2675 Stock Overview
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥14.32 |
52 Week High | CN¥20.15 |
52 Week Low | CN¥12.05 |
Beta | 0.30 |
1 Month Change | -5.79% |
3 Month Change | -18.22% |
1 Year Change | -9.48% |
3 Year Change | -24.87% |
5 Year Change | 17.96% |
Change since IPO | 140.34% |
Recent News & Updates
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Mar 15Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark
Feb 27Shareholder Returns
2675 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -11.3% | -4.9% | -2.2% |
1Y | -9.5% | -20.7% | -14.8% |
Return vs Industry: 002675 exceeded the CN Biotechs industry which returned -20.7% over the past year.
Return vs Market: 002675 exceeded the CN Market which returned -14.8% over the past year.
Price Volatility
2675 volatility | |
---|---|
2675 Average Weekly Movement | 6.7% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.1% |
10% most volatile stocks in CN Market | 11.4% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002675's share price has been volatile over the past 3 months.
Volatility Over Time: 002675's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 2,174 | Zhi Gang Luo | https://www.dcb-group.com |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Fundamentals Summary
2675 fundamental statistics | |
---|---|
Market cap | CN¥12.17b |
Earnings (TTM) | CN¥262.79m |
Revenue (TTM) | CN¥3.43b |
44.9x
P/E Ratio3.4x
P/S RatioIs 2675 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2675 income statement (TTM) | |
---|---|
Revenue | CN¥3.43b |
Cost of Revenue | CN¥1.92b |
Gross Profit | CN¥1.51b |
Other Expenses | CN¥1.25b |
Earnings | CN¥262.79m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | 0.32 |
Gross Margin | 44.06% |
Net Profit Margin | 7.67% |
Debt/Equity Ratio | 14.7% |
How did 2675 perform over the long term?
See historical performance and comparison